On June 12, AstraZeneca and Eli Lilly terminated their two Phase III clinical...
Another BACE inhibitor fails in phase III trials
On June 12, AstraZeneca and Eli Lilly terminated their two Phase III clinical trials of oral amyloid targeting β-secretase (BACE) inhibitor lanabecestat in Alzheimer’s disease (AD). The partners made the decision to terminate AMARANTH (NCT02245737) and the DAYBREAK-ALZ (NCT02783573) trials after an independent data monitoring committee concluded they were unlikely to meet primary endpoints based on interim analysis. The related AMARANTH extension trial (NCT02972658) will also be discontinued. This termination is preceded by recent failures of BACE inhibitors in late stage clinical development for the treatment of AD.
Laser Microdissection with PALM MicroBeam Technology
Its laser microdissection with PALM MicroBeam technology allows for contact-free and uncontaminated specimen collection from specific compartments of skin and hair follicles for use in next-generation sequencing analysis.
Zepatier for the Treatment of Chronic Hepatitis C GT1 and GT4 Infection
Zepatier is a once-daily, oral selective combination of nonstructural 5A (NS5A) replication complex inhibitor elbasvir (50mg) and non-structural 3/4A protease inhibitor grazoprevir (100mg).
NIH trial to assess vaccine against respiratory syncytial virus
US NIH division the National Institute of Allergy and Infectious Diseases (NIAID) has initiated a Phase I clinical trial to evaluate an investigational intranasal vaccine called SeVRSV to protect from respiratory syncytial virus (RSV).
ViiV reports positive Phase III outcomes for two-drug HIV regimen
GSK’s ViiV Healthcare has reported positive headline data from the Phase III GEMINI clinical programme of its two-drug regimen of dolutegravir and lamivudine for treatment-naïve adults with HIV-1 infection.
Afinitor Disperz (everolimus) for the Treatment of TSC-Associated Partial-Onset Seizures
Afinitor Disperz® (everolimus) is indicated for the treatment of tuberous sclerosis complex (TSC) associated partial-onset seizures in adult and paediatric patients.
State-of-the-art Skin and Hair Research Preclinical and Clinical Services
Monsterium Laboratory's Laser Capture Microdissection service utilises PALM MicroBeam technology for uncontaminated specimen collection from specific compartments of skin and hair follicles for ribonucleic acid (RNA), DNA and protein isolation.
May’s top news stories
Abivax unveiled new data that may suggest its clinical candidate ABX464 could be a safe, functional cure for human immunodeficiency virus (HIV), as well as a method to treat inflammatory diseases; and Cancer Research UK and Experimental Cancer Medicine Centres (ECMC) Network joint venture (JV) Combinations Alliance started the SeluDex trial, a Phase I clinical study to evaluate selumetinib in combination with dexamethasone for treating leukaemia.
Parsabiv™ (etelcalcetide) for the Treatment of Secondary Hyperparathyroidism (SHPT)
Parsabiv™ (etelcalcetide) is an intravenous injectable calcimimetic agent developed by Amgen for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) that were previously treated with haemodialysis.
Abivax believes it has made progress towards HIV cure
Abivax has unveiled new data that may suggest its clinical candidate ABX464 could be a safe, functional cure for human immunodeficiency virus (HIV), as well as a method to treat inflammatory diseases.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.